Physician profile
Sohail Nasim
NPI 1174623920
$1,024.46
in general payments reported to CMS, 2019-2025
17 companies · $101 in 2025
The $101 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2021: $20.34 · 2022: $40.66 · 2023: $240 · 2024: $289 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $630.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $629.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $176.03 | 2023 | Ingrezza |
| Abbott Laboratories | $137.11 | 2019 | |
| Medtronic Vascular, INC. | $131.48 | 2019 | |
| Ardelyx, INC. | $130.83 | 2024 | Xphozah 30 Mg, Ibsrela |
| Penumbra, INC. | $100.78 | 2025 | Penumbra System |
| Outset Medical INC | $78.62 | 2024 | |
| Amgen INC. | $73.77 | 2019-2024 | Parsabiv, Epogen, Tavneos |
| Novo Nordisk INC | $41.49 | 2022-2023 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $28.46 | 2024 | |
| Calliditas Therapeutics US INC. | $23.20 | 2024 | |
| Avanir Pharmaceuticals, INC. | $22.91 | 2019 | |
| Horizon Therapeutics Plc | $22.16 | 2022 | |
| Sun Pharmaceutical Industries INC. | $20.34 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.16 | 2019 | |
| Phadia US INC. | $18.12 | 2023 | Immunocap |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sohail Nasim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.